As of September 30, 2025, Immunovant’s (IMVT) cash and cash equivalents totaled approximately $521.9 million, providing runway for announced indications through GD readout expected in 2027.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMVT: